Metoprolol
Treatment for Atrial Fibrillation
Typical Dosage: Metoprolol succinate 25-200 mg daily
Effectiveness
80%
Safety Score
70%
Clinical Trials
31
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Metoprolol succinate 25-200 mg daily
Time to Effect
1-3 days
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$575
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$676
Prescription Access Economics
Annual Societal Loss per Patient
$770
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$375/year
Time Cost
$270/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$75/year
Potential OTC Price
$30/year
Estimated if OTC available
Early Treatment Benefit
+0.10 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATEMissed Diagnosis Risk
LOWRequires Monitoring
YesNeeds lab work/checkups
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
15 completed trials for Metoprolol in Atrial Fibrillation
Rate Control in Atrial Fibrillation II
NCT02695992COMPLETEDPHASE4
122 participants
INTERVENTIONAL
Rud, Norway
Started: Feb 1, 2016
Effect of BMS-914392 on Pharmacokinetics of Metoprolol
NCT01211821COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Lenexa, United States
Started: Sep 1, 2010
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
NCT01281787COMPLETEDPHASE3
320 participants
INTERVENTIONAL
Milan, Italy
Started: Apr 1, 2008
RATe Control in Atrial Fibrillation
NCT00313157COMPLETEDPHASE3
80 participants
INTERVENTIONAL
Rud, Norway
Started: Apr 1, 2006
Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery
NCT00784316COMPLETEDPHASE4
316 participants
INTERVENTIONAL
Kuopio, Finland
Started: Aug 1, 2007
Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery
NCT03943927COMPLETEDNA
107 participants
INTERVENTIONAL
Nashville, United States
Started: Mar 5, 2021
Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery
NCT00198614COMPLETEDNA
650 participants
INTERVENTIONAL
Suita, Japan
Started: Jan 1, 2005
Diltiazem vs. Metoprolol in the Acute Management of AF in Patients With HFrEF
NCT02938260COMPLETED
48 participants
OBSERVATIONAL
Started: Oct 1, 2016
Intravenous Administration of Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery
NCT00783900COMPLETEDPHASE4
316 participants
INTERVENTIONAL
Kuopio, Finland
Started: Jan 1, 2007
Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
NCT00953212COMPLETEDPHASE3
304 participants
INTERVENTIONAL
Portland, United States
Started: Aug 1, 2009
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
NCT01970501COMPLETEDPHASE2
267 participants
INTERVENTIONAL
Anchorage, United States +96 more
Started: Apr 1, 2014
Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department
NCT02248753COMPLETEDNA
437 participants
INTERVENTIONAL
Amsterdam, Netherlands +14 more
Started: Oct 1, 2014
Rate Control in Atrial Fibrillation
NCT01655303COMPLETEDPHASE4
90 participants
INTERVENTIONAL
Tehran, Iran
Started: Feb 1, 2011
Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
NCT01914926COMPLETEDPHASE4
54 participants
INTERVENTIONAL
Brooklyn, United States
Started: Jun 1, 2009
Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)
NCT04991896COMPLETED
81 participants
OBSERVATIONAL
Chios, Greece
Started: Jan 1, 2020
Showing 20 of 32 total trials